There are currently 42 active clinical trials seeking participants for COVID19 research studies. The states with the highest number of trials for COVID19 participants are Florida, Texas, California and New York.
KIDney Injury in Times of COVID-19 (KIDCOV)
NCT04705766
Recruiting
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race/ethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race/ethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine sam... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: UCSF, San Francisco, California +2 locations
Conditions: SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury
Register for Updates
COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications
NCT04535128
Recruiting
Novel coronavirus 2019 (COVID-19) has emerged as a major international public health concern. While much of the morbidity and mortality associated with COVID-19 has been attributed to acute respiratory distress syndrome (ARDS) or end-organ failure, emerging data suggest that disorders of coagulation, in particular hypercoagulability and venous thromboembolism (VTE), may represent an additional major, and possibly preventable, complication (Wu C, et al. JAMA Intern Med. 2020 Mar 13. [Epub ahead o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/03/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Covid19, Thrombosis Embolism, DVT, Pulmonary Embolism, Myocardial Infarction, Stroke
Register for Updates
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
NCT04956445
Recruiting
Collection of SARS-COV-2 Secretions and Serum for Countermeasure Development (aka ClinSeqSer) is an observational study to understand natural history of SARS-COV-2 infections among special populations and characterise post-covid morbidity through immune response, virus genome sequencing, cytokine response, and virus shedding. Given the descriptions of infection course of patients over the outbreak of 2003 (SARS-Cov01) and since January 2019 in China and Europe, and now worldwide: Acutely infect... Read More
Gender:
All
Ages:
Between 6 months and 120 years
Trial Updated:
12/20/2023
Locations: Tulane University Medical Center, New Orleans, Louisiana +1 locations
Conditions: Covid19
Register for Updates
COVID-19 International Drug Pregnancy Registry
NCT05013632
Recruiting
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
11/14/2023
Locations: Pregistry, Los Angeles, California
Conditions: Covid19
Register for Updates
COVID-19 Vaccines International Pregnancy Exposure Registry
NCT04705116
Recruiting
The objective of the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER) is to evaluate obstetric, neonatal, and infant outcomes among women vaccinated during pregnancy with a COVID-19 vaccine. Specifically, the C-VIPER will estimate the risk of obstetric outcomes (spontaneous abortion, antenatal bleeding, gestational diabetes, gestational hypertension, intrauterine growth restriction, postpartum hemorrhage, fetal distress, uterine rupture, placenta previa, chorioamnionitis, C... Read More
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
11/14/2023
Locations: Pregistry, Los Angeles, California
Conditions: Covid19
Register for Updates
The Nanowear Wearable Covid-19 Observational and Analysis Trend
NCT04717024
Recruiting
The NanoCOAT study is a multi-center, prospective, non-randomized, feasibility, observational, non-significant risk study. The NanoCOAT study will enroll a minimum of 10 and a maximum of 100 subjects in a potential for a multi-site in order to collect data and analyze physiological and biometric trends due to Covid-19.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey +1 locations
Conditions: Covid19
Register for Updates
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
NCT04896606
Recruiting
The 2019 Severe Acute Respiratory Syndrome (SARS) is a global pandemic secondary to a novel coronavirus - SARS-CoV-2. The reported case-fatality ratio for SARS-CoV-2 in the United States is 1.8% with a current death toll of >300,000 and climbing.4 There is no accepted standard of care or FDA approved therapies for treatment of COVID-19. Virus specific cytotoxic T lymphocytes (CTLs) have become an important part of the treatment landscape for viral reactivation post hematopoietic and solid organ... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/24/2023
Locations: New York Medical College, Valhalla, New York +3 locations
Conditions: Covid19
Register for Updates
Pilot Study for PET/MR Imaging of Covid-19
NCT04954248
Recruiting
The primary goal of this project is to study the feasibility of a prototype brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of metabolism and perfusion in Covid-19 negative and positive/once positive subjects. This study serves as a pilot study for establishing an imaging protocol for combined PET and MR derived functional information as well as MRI acquired anatomical information.
Gender:
All
Ages:
21 years and above
Trial Updated:
08/19/2023
Locations: Stanford University, Palo Alto, California
Conditions: Brain Diseases, Covid19
Register for Updates
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
NCT04562285
Recruiting
The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Covid19
Register for Updates
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
NCT05046561
Recruiting
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
Gender:
All
Ages:
18 years and above
Trial Updated:
09/08/2022
Locations: Luna Research, Coral Gables, Florida +12 locations
Conditions: Covid19
Register for Updates
Gazelle COVID-19 Test Clinical Accuracy Protocol
NCT04987918
Recruiting
Gazelle COVID-19 is a fluorescent lateral flow immunoassay and accompanying Reader intended for the qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal swab specimens from individuals who are suspected of COVID-19 by their healthcare provider within 5 days of symptom onset. The study will be conducted To obtain data to measure the positive percent agreement and negative percent agreement of the Gazelle COVID-19 Test compared to Reverse Transcriptase Polymerase Chain Reaction (... Read More
Gender:
All
Ages:
All
Trial Updated:
08/08/2022
Locations: Northwest Pathology drive thru site, Bellingham International Airport, Bellingham, Washington
Conditions: Covid19
Register for Updates
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
NCT04798001
Recruiting
This study evaluates an investigational vaccine that is designed to protect humans against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease. The investigational vaccine, MV-014-212, is a live attenuated vaccine against respiratory syncytial virus (RSV) that is expressing the spike (S) protein of SARS-CoV-2. MV-014-212 is administered as drops or a spray in the nose. Specifically, this study analyzes the safety of, and the immune response to, the vaccine when administered... Read More
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
08/01/2022
Locations: Johnson County Clin-Trials, Lenexa, Kansas +1 locations
Conditions: Covid19
Register for Updates